Publications
54
Citations
869
Est. group size
—
Recurring co-author estimate
Active years
19
Publishing since 2008
Typically publishes in teams of ~11 · 3% small-team papers (≤3 authors) · across 18 venues
- Description and management strategies of prespecified treatment emergent adverse events (TEAEs) amongst patients (pts) treated with 1L enfortumab vedotin (EV) + pembrolizumab (P) for la/mUC in a real-world setting.
Journal of Clinical Oncology · 2026
- Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer
Patient · 2026
- Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants
Vaccine · 2025
- Recent trends in US real-world first-line (1L) treatment patterns for patients with locally advanced or metastatic urothelial carcinoma (la/mUC).
Journal of Clinical Oncology · 2025
- Quantifying patient preferences for bacillus Calmette-Guérin (BCG) and PD-(L)1 inhibitors in high-risk non-muscle invasive bladder cancer (NMIBC): A discrete choice experiment.
Journal of Clinical Oncology · 2025
- Evaluation of surrogate endpoints in muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
Journal of Clinical Oncology · 2025
- EE610 Population Impact of Performing BRCA1/2 Testing to Guide Metastatic Castration-Resistant Prostate Cancer Treatment in Spain
Value in Health · 2025
- A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
The Pediatric Infectious Disease Journal · 2024
- Economic Impact of Bladder Cancer in the USA
PharmacoEconomics - Open · 2024
- Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey
Urologic Oncology Seminars and Original Investigations · 2024
- MP68-16 REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR NOVEL HORMONAL THERAPY AND TAXANE USE
The Journal of Urology · 2024
- Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers
Journal of Comparative Effectiveness Research · 2024
- Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational study derived from the national hospital discharge claims database in Italy
BMC Cancer · 2024
- Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.
Journal of Clinical Oncology · 2024
- Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial
Vaccine · 2023
- Journal of Clinical Oncology×9
- Vaccine×4
- Open Forum Infectious Diseases×3
- The Pediatric Infectious Disease Journal×2
- Human Vaccines & Immunotherapeutics×2
- Rebecca Wallihan
Medicine · The Ohio State University
- William J. Barson
Medicine · The Ohio State University
- Julio A. Ramírez
Medicine · Purdue University West Lafayette
- Nobuhiro Asai
Medicine · University of Michigan
- Suzanne Dawid
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile